The first step is to identify and validate a T-cell clone specific for the desired epitope; this can either be generated in- house or in-licensed, as appropriate. The T-Cell Receptor (TCR) from the clone is then isolated and re-engineered into a soluble format through the introduction of a new inter-chain disulphide bond that is buried [...]

Like antibodies, TCRs contain 6 hypervariable complementary determining regions (CDRs) which form the binding epitope contact surface. Immunocore engineers these CDR regions to increase the affinity of the mTCR for its target while maintaining specificity, typically resulting in mTCRs with low pM affinities and long target residence times. Read more »

As the former CEO of Avidex Limited, James has in-depth knowledge of Immunocore’s mTCR technology as well as a wealth of prior experience in the international biotech community. Former CFO of British Biotech, prior to leading Avidex for 7 years, James also sits as a non-executive director on the boards of GW Pharmaceuticals plc and [...]

The final step is to generate and validate fusions to the desired effector function. The mTCR is linked to the effector, an anti-CD3 scFv. This mediates T cell redirection and is a clinically-validated, highly potent therapeutic mechanism of action.  Read more »

Dr Jakobsen founded Avidex in March 1999 and joined Avidex as full-time Chief Scientific Officer and Executive Board member in July 2000. Bent founded Avidex whilst he was at the Institute of Molecular Medicine (IMM) in Oxford, where he was head of the Immune Receptor Group from 1993 to July 2000. This group is recognised [...]

Dominic has ten years’ experience across all phases of drug development having previously worked at Amgen and AstraZeneca. He obtained his MRCP in 1999 working in the NHS and his Master of Arts/medical/surgical degrees from Cambridge. He has published peer-reviewed articles on various elements of scientific and clinical research including work in Nature and the [...]

Having gained a PhD in molecular biology from Cardiff University, Steve Megit has spent 10 years working in biotech business development on a variety of small molecule and biological therapeutics.

Yvonne has worked in both small biotech and large pharma companies in the early development of small molecules, cell therapy and biologics for cancer and autoimmune disease. She obtained her PhD from the University of Wales, College of Medicine in 2000.